Squarepoint’s Dare Bioscience DARE Stock Holding History

Squarepoint’s Portfolio DARE Stock Details DARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-968	Closed	-$17K	–	2966
2022 Q1	$17K	Buy	+968	New	+$18.3K	﹤0.01%	2720
2021 Q2	–	Sell	-11,844	Closed	-$240K	–	3327
2021 Q1	$240K	Buy	+11,844	New	+$289K	﹤0.01%	2575

Other funds holding DARE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SAM

Soviero Asset Management New York $200M AUM 134.59% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

FFS

Founders Financial Securities Towson, Maryland $1.77B AUM 17.63% 1-Year Est. Return

FFA

Founders Financial Alliance Raleigh, North Carolina $555M AUM 22.31% 1-Year Est. Return

Squarepoint's DARE Position: Q2 2022 in Review

Squarepoint sold out of Dare Bioscience (DARE) in Q2 2022, closing a stake of 968 shares — an estimated $17K sold.

Squarepoint first reported a position in DARE in Q1 2021 and held it in 2 quarters. The position peaked at $240K in Q1 2021. 36 funds tracked by Wall St. Rank hold DARE as of Q2 2022.

Squarepoint reported no remaining Dare Bioscience position as of Q2 2022 after selling out during the quarter.
Squarepoint sold 968 Dare Bioscience shares in Q2 2022, an estimated $17K.
Squarepoint first reported a position in Dare Bioscience in Q1 2021 and held it in 2 quarters.
Squarepoint's Dare Bioscience position peaked at $240K in Q1 2021.
36 funds tracked by Wall St. Rank held Dare Bioscience as of Q2 2022.

Based on Squarepoint's 13F filing for Q2 2022, filed 15 Aug 2022.